CD40 agonist-induced IL-12p40 potentiates hepatotoxicity. Issue 1 (30th May 2020)

• Record Type: Journal Article
• Authors: Bonnans, Caroline; Thomas, Graham; He, Wenqian; Jung, Breanna; Chen, Wei; Liao, Min; Heyen, Jonathan; Buetow, Bernard; Pillai, Smitha; Matsumoto, Diane; Chaparro-Riggers, Javier; Salek-Ardakani, Shahram; Qu, Yan
• Is Part Of: Journal for immunotherapy of cancer. Volume 8:Issue 1(2020)
• Publication Date: 2020-05-30
• Subjects: immunotherapy -- drug evaluation, preclinical -- cytotoxicity, immunologic -- cytokines -- costimulatory and inhibitory t-cell receptors; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-000624
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: CD40 is a compelling target for cancer immunotherapy, however, attempts to successfully target this pathway have consistently been hampered by dose-limiting toxicity issues in the clinic that prevents the administration of efficacious doses. Methods: Here, using cytokine and cytokine receptor depletion strategies in conjunction with a potent CD40 agonist, we investigated mechanisms underlying the two primary sources of CD40 agonist-associated toxicity, hepatotoxicity and cytokine release syndrome (CRS). Results: We demonstrate that CD40 agonist -induced hepatotoxicity and CRS are mechanistically independent. Historical data have supported a role for interleukin-6 (IL-6) in CRS-associated wasting, however, our findings instead show that an inflammatory cytokine network involving TNF, IL-12p40, and IFNγ underlie this process. Deficiency of TNF or IFNγ did not influence CD40-induced hepatitis however loss of IL-12p40 significantly decreased circulating concentrations of liver enzymes and reduced the frequency of activated CD14 + MHCII + myeloid cells in the liver, indicating a role for IL-12p40 in liver pathology. Conclusions: As clinical research programs aim to circumnavigate toxicity concerns while maintaining antitumor efficacy it will be essential to understand which features of CD40 biology mediate antitumor function to develop both safe and efficacious agonists.